Pharmacy Choice Newsletter - September 2008
|
Hello Member, in this month's issue:
|
|
|
Sponsor - Biocodex, Inc.
|
Recommendation Opportunities For You!
Did you know... that over 23% of patients suffer the side effects of antibiotics! Biocodex, Inc., makers of Florastor would like to help you offer relief to those who suffer with intestinal issues during antibiotic therapy. With hundreds of studies to support it and manufactured to pharmaceutical grade, Florastor is one of the best probiotic options available. Florastor is non-pathogenic yeast, which means (unlike bacterial probiotics) it is not attenuated when taken at the same time as an antibiotic. Start and stop Florastor the same day as your antibiotic and watch your antibiotic therapy compliance rates improve! One packet or capsule twice daily is all your patients need.
Florastor KIDS is a great alternative to parents whose children have gastroenteritis, or non-specific diarrhea. Florastor KIDS treats many different forms of diarrhea helping your patients to better control their bowels. Go to www.sboulardii.com and read all there is to see. There is even a learning center with movies for you to better understand the concept of probiotics and why they are such a safe alternative to Imodium or Pepto for children and seniors.
Looking for bottom line contributions?
Can a probiotic contribute to the bottom line? We think so!
- 40% profit per recommendation
- Florastor is for everyone, from 2 months of age and up
- 1 BID (capsule or packet)
- Florastor available as 10 caps, 20 caps and 50 caps
- Florastor KIDS available as 10 packets and 20 packets
- Restores microbial imbalance
- For all forms of diarrhea
- Strengthens intestinal immunity
- Maintains intestinal health
Florastor the number one probiotic worldwide
|
|
|
|
|
|
|
RxCareerCenter Hot Jobs
|
Each month this newsletter will spotlight several hot jobs that are attracting the most attention on RxCareerCenter.
|
|
|
|
|
|
|
|
Featured Distance CE » Taking RAAS to a New Level-Direct Renin Inhibition and Novel Approaches to Combination Therapy
|
Learning Objectives
At the completion of this program, the participant will be able to:
- Describe the physiologic rationale for RAAS blockade in managing patients with diabetes and/or hypertension
- Discuss new findings on the role of RAAS blockade in renal function and nephropathy
- Compare and contrast the safety, efficacy, and adverse effects of ACE inhibitors, ARBs, and DRIs in hypertension management and CV outcomes
- Identify appropriate novel combination therapy regimens for hypertension control in patients with diabetes
For more information, visit the Course Information Page.
|
|
ACPE Accreditation Information
Medical Education Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
|
|
|
|
|
|
Featured Article » Insomnia Treatment: Conventional and Novel Therapeutic Strategies
|
This month's CE program discusses the recognition and treatment of insomnia. Insomnia manifests itself as difficulty falling asleep, staying asleep or nonrefreshing sleep combined with daytime fatigue and impairment of function. Studies undertaken between 1989 and 2003 demonstrate the prevalence of the problem.
Read Entire Article
|
|
|
|
|
Disease Focus
|
September Disease Focus » Prostate Cancer
September's disease focus, Prostate cancer, was featured in last month's newsletter. For more information about Prostate cancer visit our Prostate cancer awareness page.
October Disease Focus » Celiac Disease
Celiac disease (CD) is a condition triggered by the consumption of the protein gluten that is typically found in breads, pastas, and many other foods containing wheat, barley, and rye. This disease leads to the damage of the tiny hair-like projections, called villi, which are found on the intestinal wall lining, and results in the intestines inability to absorb nutrients such as vitamins, proteins, minerals, and fats. CD is probably more common than researchers previously believed and according to recent studies by the University of Chicago, Celiac Disease Center can be found in 1 in 133 people. However, if there is a first degree relative diagnosed with CD, the prevalence is closer to 1 in 22 people. CD is typically under-diagnosed due to fact that is resembles many other conditions that result in malabsorption and similar symptoms are reported by affected individuals. Symptoms of CD include: intermittent diarrhea, abdominal pain, bloating, weight loss, and foul smelling discolored feces.
Diagnosis of CD can be confirmed by a blood test that detects high levels of antibodies like: anti-gladin, anti-endomysium, and anti-tissue transglutaminase. These antibodies are present in higher than normal levels due to the body's identification of gluten in the intestinal tract as a foreign substance and the resulting effort to eliminate the substance. Although there currently is not cure for CD, it can usually be managed by diet modifications to eliminate or minimize ingestion of gluten containing foods. Avoidance of gluten may be essential in preventing complications such as malnutrition, loss of calcium and bone density (osteoporosis), lactose intolerance, intestinal lymphoma, and bowel cancer.
For more information about Celiac Disease visit our Celiac Disease awareness page.
|
|
|
|
|
Quick Poll
|
Last Month's Poll Results
Which of the following are you informing your patients about for their new HFA inhaler that may be different from their old CFC inhaler?
- 43% - HFA inhalers may taste different than their CFC inhaler.
- 7.9% - HFA inhalers may provide a stream of drug that may feel softer than that of their CFC inhaler
- 2.9% - HFA inhalers may need to be primed and cleaned differently than that of their CFC inhaler
- 46% - All of the above
|
| September Quick Poll |
|
What do you believe will be the result of the government's recommendation for children from the age of six months to 18 years be vaccinated for influenza in 2008?
|
|
|
|
|
|
|
|
Industry Headlines » Where Do You Get Your News?
|
|
|
|
|
This Month's Palm Pilot Goes To...
|
Congratulations, CINDY JOHNSON, who will receive a Palm Pilot courtesy of Pharmacy Choice. Remember, to be eligible for our monthly drawing, all you have to do is refer a friend to us, forward this newsletter, take one of our short surveys or take the new Needs Assessment Survey viewable when you login at RxSchool. Please login to participate in one of our career surveys.
|
|
|
|
|
Coming Soon
|
| New Live CE from RxSchool |
- Oct 2 - Headache: Therapeutic Update on Prevention & Treatment
- Oct 21 - Influenza 2008: A Review and Update of Treatment and Prevention Options
|
| Disease State |
- Upcoming Disease State for November: Gastro Esophageal Reflux
|
|
| Forward to a Friend |
Forward this newsletter to friend and you will be automatically entered in our monthly Palm Pilot drawing! |
|
|
|
|
|
© 2008 Pharmacy Choice (PC) - All rights reserved.
2601 Blake St Suite 400 | Denver, Colorado 80205
888-862-4415
Disclaimer:
The information contained in this newsletter is intended as an educational aid only. All Treatments or procedures are intended to serve
as an information resource for pharmacists, physicians or other competent healthcare professionals performing the consultation or
evaluation of patients and must be interpreted in view of all attendant circumstances, indications and contraindications. The use of any
of these products or information is at your sole risk. These products are provided "as is" and "as available" for use, without warranties
of any kind, either express or implied. PC makes no representation or warranty as to the accuracy, reliability, timeliness,
usefulness or completeness of any of the information contained in the products. Additionally, PC makes no representation or
warranties as to the opinions or other service or data you may access, download or use as a result of use of the PC products.
All implied warranties of merchantability and fitness for a particular purpose or use are hereby excluded. PC does not assume
any responsibility or risk for your use of the PC products or information.
|
|
|
|
